Brought to you by 
Merck invests in NGM, gets options to license new biologics
Feb 2015
Executive Summary
Merck & Co. Inc. paid $94mm up front and $106mm for a 15% equity stake in NGM Biopharmaceuticals Inc., in exchange for the chance to further develop and sell the private biotech’s preclinical biologic therapies for multiple indications.
Deal Industry
-
Biotechnology
- Drug Discovery Tools
- Large Molecule
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Includes Contract
- Co-Promotion
- Includes Equity
- R+D and Marketing-Licensing
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merck invests in NGM, gets options to license new biologics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice